Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States. The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000.

BMY

Financials

Bristol-Myers Squibb Company Common Stock

Noticias

Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?

How Bristol Is Building On Its $74 Billion Celgene Buyout With New 'Molecular Glue'

Most Investors Get Comfortable First – and Miss the Biggest Moves Because of It

UBS reitera su calificación de Bristol-Myers Squibb por el potencial de su pipeline

AGEN vs. IOVA: Which Cancer Biotech Stock Has More Upside Potential?

Eli Lilly to Expand Vaccine Pipeline With Three Biotech Buyouts

Bristol-Myers Squibb Is Quietly Building Its Next Growth Cycle (NYSE:BMY)

Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?

How Agenus' Pipeline Progress Unlock Its Next Growth Phase

Here's Why You Should Add JANX Stock to Your Portfolio Now

Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock

Wall Street Loves to Make Predictions — but This Trader Does Something Else